This group encompasses acute promyelocytic leukemia (APL) with PML::RARA fusion, which is distinct due to its responsiveness to targeted therapy with all-trans retinoic acid (ATRA) and arsenic trioxide. This evidence concerns the gene PML and acute promyelocytic leukemia.